For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of Vyndamax and Attruby represents a genuine change. These innovative therapies stabilize the transthyretin protein, preventing its harmful build-up and alleviating the severity of the